A phase 2 clinical trial of personalized peptide vaccination for castration-resistant prostate cancer (CRPC) patients with slight bone marrow suppressio
Phase 2
- Conditions
- Castration-resistant prostate cancer
- Registration Number
- JPRN-UMIN000019802
- Lead Sponsor
- Cancer Vaccine Center, Kurume University School of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
he following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2)Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3) Patients with the past history of severe allergic reactions. 4) Patients who are judged inappropriate for the clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method